Path to Long-Term HIV Remission
▼ Summary
– Approximately 40 million people worldwide live with HIV, requiring lifelong antiretroviral treatment since no cure exists.
– In 2025, two independent trials demonstrated a potential functional cure using engineered antibody infusions to control HIV without continuous medication.
– The FRESH trial in South Africa showed four of 20 participants maintained undetectable HIV levels for a median of 1.5 years post-intervention.
– The RIO trial in the UK and Denmark reported six of 34 participants achieved viral control for at least two years without antiretrovirals.
– Researchers plan larger trials to optimize antibody treatments, addressing challenges like cost and stigma associated with current HIV therapies.
Globally, nearly 40 million individuals are living with HIV, a condition that has shifted from a fatal diagnosis to a manageable chronic illness thanks to medical advances. Despite these improvements, a true cure has remained out of reach, requiring those infected to depend on lifelong antiretroviral therapy to keep the virus in check. However, recent research offers a promising glimpse into a future where long-term viral suppression might be possible without daily medication.
In 2025, two separate clinical trials demonstrated that a functional cure, where the virus is controlled without ongoing treatment, could be achievable. Both studies utilized specially designed antibody infusions, and in each case, a number of participants maintained undetectable viral loads long after their therapy concluded, without needing further antiretroviral drugs.
One of these studies, known as the FRESH trial, was directed by virologist Thumbi Ndung’u at the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa. Out of 20 participants, four successfully suppressed HIV for a median duration of one and a half years without medication. In the parallel RIO trial, conducted in the United Kingdom and Denmark under the guidance of Sarah Fidler from Imperial College London, six out of 34 individuals preserved viral control for at least two years post-intervention.
These groundbreaking proof-of-concept studies illustrate that the body’s immune response can be effectively mobilized to combat HIV. Scientists are now preparing to expand this research with larger, more diverse trials to refine the antibody approach and determine how it can benefit a broader population.
Sarah Fidler expressed strong optimism about the potential impact of this treatment strategy. She highlighted that these are long-acting agents whose benefits continue even after they have left the system, a feature not seen with previous HIV therapies. For many people living with HIV, daily pills or bi-monthly injections present not only a practical burden but also financial and social hurdles, including stigma. Fidler noted that for the past 15 to 20 years, the research community has been intensely focused on finding better solutions beyond lifelong drug regimens.
While antiretroviral drugs enable people with HIV to lead healthy lives, their life expectancy typically remains shorter than that of HIV-negative individuals. The quest for a functional cure represents a critical step toward normalizing life for those affected and reducing the everyday challenges associated with current treatment options.
(Source: Ars Technica)
